Notice: This company has been marked as potentially delisted and may not be actively trading. Apricus Biosciences (APRI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends APRI vs. ALXO, EPIX, AVTE, SLS, CELU, CRVO, BYSI, MNOV, CTXR, and IOBTShould you be buying Apricus Biosciences stock or one of its competitors? The main competitors of Apricus Biosciences include ALX Oncology (ALXO), ESSA Pharma (EPIX), Aerovate Therapeutics (AVTE), SELLAS Life Sciences Group (SLS), Celularity (CELU), CervoMed (CRVO), BeyondSpring (BYSI), MediciNova (MNOV), Citius Pharmaceuticals (CTXR), and IO Biotech (IOBT). These companies are all part of the "medical" sector. Apricus Biosciences vs. ALX Oncology ESSA Pharma Aerovate Therapeutics SELLAS Life Sciences Group Celularity CervoMed BeyondSpring MediciNova Citius Pharmaceuticals IO Biotech Apricus Biosciences (NASDAQ:APRI) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings. Do analysts prefer APRI or ALXO? ALX Oncology has a consensus target price of $12.50, indicating a potential upside of 832.84%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than Apricus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apricus Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to APRI or ALXO? In the previous week, ALX Oncology had 13 more articles in the media than Apricus Biosciences. MarketBeat recorded 13 mentions for ALX Oncology and 0 mentions for Apricus Biosciences. ALX Oncology's average media sentiment score of 0.45 beat Apricus Biosciences' score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media. Company Overall Sentiment Apricus Biosciences Neutral ALX Oncology Neutral Which has higher earnings and valuation, APRI or ALXO? Apricus Biosciences has higher revenue and earnings than ALX Oncology. Apricus Biosciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApricus Biosciences$5.76M3.42$320K-$0.99-0.71ALX OncologyN/AN/A-$160.80M-$2.98-0.45 Is APRI or ALXO more profitable? ALX Oncology's return on equity of -93.02% beat Apricus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Apricus BiosciencesN/A -216.45% -153.13% ALX Oncology N/A -93.02%-70.67% Which has more risk and volatility, APRI or ALXO? Apricus Biosciences has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Does the MarketBeat Community believe in APRI or ALXO? Apricus Biosciences received 183 more outperform votes than ALX Oncology when rated by MarketBeat users. Likewise, 69.91% of users gave Apricus Biosciences an outperform vote while only 62.67% of users gave ALX Oncology an outperform vote. CompanyUnderperformOutperformApricus BiosciencesOutperform Votes23069.91% Underperform Votes9930.09% ALX OncologyOutperform Votes4762.67% Underperform Votes2837.33% Do institutionals and insiders hold more shares of APRI or ALXO? 19.9% of Apricus Biosciences shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 2.3% of Apricus Biosciences shares are held by company insiders. Comparatively, 33.4% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryALX Oncology beats Apricus Biosciences on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Apricus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRI vs. The Competition Export to ExcelMetricApricus BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.72M$7.07B$5.33B$8.88BDividend YieldN/A8.03%4.98%4.04%P/E Ratio-0.7111.23131.8417.44Price / Sales3.42384.151,258.8298.06Price / CashN/A49.2239.0436.42Price / Book2.419.136.295.90Net Income$320,000.00$153.49M$118.56M$224.79M Apricus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APRIApricus BiosciencesN/A$0.70-1.4%N/A+467.3%$19.72M$5.76M-0.71N/AGap UpALXOALX Oncology3.2144 of 5 stars$1.45-4.0%N/A-84.9%$80.59MN/A-0.4040Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageEPIXESSA Pharma3.0226 of 5 stars$1.80+1.7%N/A-63.5%$79.86MN/A-2.9050Gap UpAVTEAerovate Therapeutics1.6148 of 5 stars$2.72-0.7%N/A-81.9%$79.68MN/A-0.8751Earnings ReportShort Interest ↓SLSSELLAS Life Sciences Group1.3104 of 5 stars$1.23+6.0%N/A+39.9%$79.13M$1M-1.3416Short Interest ↑CELUCelularity0.3674 of 5 stars$3.55+14.9%N/A+6.0%$78.06M$22.77M0.00220Short Interest ↑High Trading VolumeCRVOCervoMed1.2035 of 5 stars$12.54+0.1%N/A+13.9%$77.38M$7.14M0.004Earnings ReportAnalyst ForecastShort Interest ↑News CoverageGap DownBYSIBeyondSpringN/A$1.94+3.7%N/A+91.8%$75.72M$1.88M0.0080Gap UpHigh Trading VolumeMNOVMediciNova0.5425 of 5 stars$1.53-2.5%N/A+4.9%$75.05M$1M-9.5610News CoverageGap DownCTXRCitius Pharmaceuticals3.2648 of 5 stars$0.41+7.9%N/A-57.5%$74.37MN/A-1.7120Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading VolumeIOBTIO Biotech2.9339 of 5 stars$1.10-10.6%N/A-9.2%$72.47MN/A-0.7630Earnings ReportAnalyst ForecastShort Interest ↓Gap UpHigh Trading Volume Related Companies and Tools Related Companies ALXO Competitors EPIX Competitors AVTE Competitors SLS Competitors CELU Competitors CRVO Competitors BYSI Competitors MNOV Competitors CTXR Competitors IOBT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APRI) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apricus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apricus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
